1-(morpholin-2-yl)ethan-1-ol | 1314908-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-(morpholin-2-yl)ethan-1-ol
• 英文别名: 2-(hydroxyethyl)morpholine；(hydroxyethyl)morpholine；morpholinylethanol；1-morpholin-2-ylethanol
• CAS: 1314908-48-9
• 化学式: C₆H₁₃NO₂
• mdl: MFCD19218832
• 分子量: 131.175
• InChiKey: ABZOPRBMPGVISK-UHFFFAOYSA-N

物化性质

• 沸点：
  226.0±15.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(morpholin-2-yl)ethan-1-ol 在 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 XPhos Pd G2 、 palladium 10% on activated carbon 、 氢气 、 potassium acetate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 二甲基亚砜 为溶剂， 反应 7.5h， 生成 tert-butyl 4-(7-fluoroimidazo[1,2-a]pyridin-3-yl)-7-((5-(2-(1-hydroxyethyl)morpholino)pyridin-2-yl)amino)-1-oxoisoindoline-2-carboxylate
  参考文献：
  名称：

  HPK1 ANTAGONISTS AND USES THEREOF

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。

  公开号：

  US20210078996A1

文献信息

• 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto
  申请人：Teegarden Bradley

  公开号：US20070207994A1

  公开（公告）日：2007-09-06

  The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及某些3-苯基-吡唑衍生物，其具有公式(Ia)和调节5-HT2A血清素受体活性的药物组合物。这些化合物及其药物组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、房颤、降低血块形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、抽动秽语综合征、躁狂症、有机或NOS精神病、精神疾病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关障碍，以及睡眠障碍、糖尿病相关障碍、进行性多灶性脑白质病等。本发明还涉及与其他药物一起或分别给药治疗5-HT2A血清素受体介导的疾病的方法。
• [EN] (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES<br/>[FR] (AZA)INDOLE, BENZOTHIOPHÈNE ET BENZOFURAN-3-SULFONAMIDES
  申请人：UCB PHARMA GMBH

  公开号：WO2018122232A1

  公开（公告）日：2018-07-05

  Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

  揭示了具有GPR17调节特性的磺胺类化合物，可用于治疗或预防各种中枢神经系统和其他疾病，特别是用于预防和治疗髓鞘疾病或紊乱。
• [EN] DESFERRITHIOCIN ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE LA DESFERRITHIOCINE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2015077655A1

  公开（公告）日：2015-05-28

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁过载与病理条件相关，如氧化应激、输血性铁过载、地中海贫血、原发性血色病、继发性血色病、糖尿病、肝病、心脏病、癌症、放射损伤、神经或神经退行性疾病、弗里德雷希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激综合征和再灌注损伤。本发明提供使用式（A）和（J）的去铁胱醇类似物的方法和药物组合物，用于治疗和/或预防这些病理条件、金属（如铁、铝、镧系元素或锕系元素（如铀））过载症状和传染病（如疟疾）。
• [EN] PROCESS FOR THE PREPARATION OF DIPHENYLPYRAZINE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS DE DIPHÉNYLPYRAZINE
  申请人：HONOUR (R&D)

  公开号：WO2017168401A1

  公开（公告）日：2017-10-05

  The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

  本发明涉及一种使用溶剂从Selexipag结晶盐制备无定形Selexipag的方法。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：METHYLGENE INC

  公开号：WO2005092899A1

  公开（公告）日：2005-10-06

  The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

  这项发明涉及一系列对抑制组蛋白去乙酰化酶（HDAC）酶活性有用的化合物。该发明还提供了一种利用这些化合物抑制细胞中组蛋白去乙酰化酶的方法，以及一种利用这些HDAC抑制剂治疗细胞增殖性疾病和病况的方法。此外，该发明提供了包含这些HDAC抑制化合物和药用可接受载体的药物组合物。